[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio8dd2dfdf":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":77},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio8dd2dfdf","美股NTRA股价翻倍，聚焦癌症复发检测","\u002Fdoc\u002Fdcio8dd2dfdf","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">美股\u003C\u002Fspan>NTRA\u003Cspan style=\"font-family: DengXian;\">总部位于德克萨斯州奥斯汀的\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">，凭借其在微小残留病灶（\u003C\u002Fspan>MRD\u003Cspan style=\"font-family: DengXian;\">）检测领域的近乎垄断地位，股价三年内翻涨约四倍，市值升至约\u003C\u002Fspan>310\u003Cspan style=\"font-family: DengXian;\">亿美元，已超越基因测序巨头\u003C\u002Fspan>Illumina\u003Cspan style=\"font-family: DengXian;\">。公司营收从\u003C\u002Fspan>2023\u003Cspan style=\"font-family: DengXian;\">年的约\u003C\u002Fspan>10\u003Cspan style=\"font-family: DengXian;\">亿美元跃升至去年的\u003C\u002Fspan>23\u003Cspan style=\"font-family: DengXian;\">亿美元，分析师预计今年将进一步增至\u003C\u002Fspan>27.7\u003Cspan style=\"font-family: DengXian;\">亿美元。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">然而，亮眼的成长轨迹也带来了估值压力。尽管\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">第一季度营收同比增长\u003C\u002Fspan>39%\u003Cspan style=\"font-family: DengXian;\">至\u003C\u002Fspan>6.97\u003Cspan style=\"font-family: DengXian;\">亿美元，超出市场预期，其股价上周仍下跌约\u003C\u002Fspan>10%\u003Cspan style=\"font-family: DengXian;\">。以\u003C\u002Fspan>10\u003Cspan style=\"font-family: DengXian;\">至\u003C\u002Fspan>11\u003Cspan style=\"font-family: DengXian;\">倍远期营收计算的高估值意味着，任何低于完美的增长数据都会令市场神经紧绷。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">美股投资网研究发现，华尔街的长期看多逻辑依然清晰：\u003C\u002Fspan>MRD\u003Cspan style=\"font-family: DengXian;\">检测市场渗透率目前仅约\u003C\u002Fspan>6%\u003Cspan style=\"font-family: DengXian;\">，\u003C\u002Fspan>Leerink Partners\u003Cspan style=\"font-family: DengXian;\">分析师\u003C\u002Fspan>Puneet Souda\u003Cspan style=\"font-family: DengXian;\">估计国内市场规模达\u003C\u002Fspan>200\u003Cspan style=\"font-family: DengXian;\">亿美元，增长空间远未释放。\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">能否将业务从学术医院延伸至社区肿瘤科医生，并在国际市场复制成功，将是决定其能否维持强劲增长的关键。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">MRD\u003Cspan style=\"font-family: DengXian;\">检测：一门比\u003C\u002Fspan>“\u003Cspan style=\"font-family: DengXian;\">早筛\u003C\u002Fspan>”\u003Cspan style=\"font-family: DengXian;\">更确定的生意\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">公众对癌症血液检测的关注，长期聚焦于\u003C\u002Fspan>Grail\u003Cspan style=\"font-family: DengXian;\">公司的\u003C\u002Fspan>Galleri\u003Cspan style=\"font-family: DengXian;\">等多癌种早期筛查产品\u003C\u002Fspan>——\u003Cspan style=\"font-family: DengXian;\">这类产品承诺通过一次抽血筛查\u003C\u002Fspan>50\u003Cspan style=\"font-family: DengXian;\">余种癌症，吸引了大量媒体报道乃至超级碗广告投放。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">但对投资者而言，更具确定性的机会实际上来自一个不那么光鲜的赛道：癌症复发检测。\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">对于刚刚完成肿瘤切除手术的患者而言，最关键的问题是：癌细胞是否已被彻底清除？许多肿瘤科医生如今借助血液检测来回答这一问题，其时效比传统影像扫描早出数月。\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">多癌种早筛技术的核心痛点在于灵敏度不足\u003C\u002Fspan>——\u003Cspan style=\"font-family: DengXian;\">尤其对乳腺癌、前列腺癌等早期癌症的检出率偏低。\u003C\u002Fspan>MRD\u003Cspan style=\"font-family: DengXian;\">检测则截然不同：由于检测起点是原始肿瘤的\u003C\u002Fspan>DNA\u003Cspan style=\"font-family: DengXian;\">，它能精准锁定目标，如同\u003C\u002Fspan>“\u003Cspan style=\"font-family: DengXian;\">狙击手\u003C\u002Fspan>”\u003Cspan style=\"font-family: DengXian;\">而非\u003C\u002Fspan>“\u003Cspan style=\"font-family: DengXian;\">广撒网\u003C\u002Fspan>”\u003Cspan style=\"font-family: DengXian;\">。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">City of Hope\u003Cspan style=\"font-family: DengXian;\">肿瘤科医生\u003C\u002Fspan>Neel Talwar\u003Cspan style=\"font-family: DengXian;\">表示：\u003C\u002Fspan>\"\u003Cspan style=\"font-family: DengXian;\">当肿瘤在影像上显现时，往往已经太晚。化疗对微小病灶的清除效果，远优于影像上已可见的宏观病灶。\u003C\u002Fspan>\"\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">Signatera\u003Cspan style=\"font-family: DengXian;\">：个性化检测构筑技术护城河\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">Natera\u003Cspan style=\"font-family: DengXian;\">的旗舰产品\u003C\u002Fspan>Signatera\u003Cspan style=\"font-family: DengXian;\">采用\u003C\u002Fspan>\"\u003Cspan style=\"font-family: DengXian;\">肿瘤知情\u003C\u002Fspan>\"\u003Cspan style=\"font-family: DengXian;\">技术路线。肿瘤切除后，\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">对该肿瘤组织进行测序，识别其独特的基因特征，再据此为患者定制个性化血液检测，用于追踪后续血样中是否存在相同突变。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">这一技术路线赋予\u003C\u002Fspan>Signatera\u003Cspan style=\"font-family: DengXian;\">在\u003C\u002Fspan>MRD\u003Cspan style=\"font-family: DengXian;\">市场的近乎垄断地位。然而，大规模普及仍面临现实障碍：商业保险公司目前仅在约\u003C\u002Fspan>25%\u003Cspan style=\"font-family: DengXian;\">的情况下为相关检测付费，覆盖约半数符合条件的患者群体，\u003C\u002Fspan>TD Cowen\u003Cspan style=\"font-family: DengXian;\">分析师\u003C\u002Fspan>Dan Brennan\u003Cspan style=\"font-family: DengXian;\">指出。\u003C\u002Fspan>Medicare\u003Cspan style=\"font-family: DengXian;\">已将此类检测纳入报销范围，但商业险的覆盖扩展，有赖于临床试验证明依据血检结果采取干预措施能够切实延长患者生存期，进而推动美国国家综合癌症网络（\u003C\u002Fspan>NCCN\u003Cspan style=\"font-family: DengXian;\">）等机构更新诊疗指南。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">目前，\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">已就\u003C\u002Fspan>Signatera\u003Cspan style=\"font-family: DengXian;\">在膀胱癌适应症向美国食品药品监督管理局（\u003C\u002Fspan>FDA\u003Cspan style=\"font-family: DengXian;\">）提交申请，并有一项显示患者生存改善的晚期临床试验数据作为支撑。\u003C\u002Fspan>Brennan\u003Cspan style=\"font-family: DengXian;\">表示，更大的市场突破将取决于更大癌种的试验结果及后续指南跟进。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">日本市场或成近期催化剂\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">在国际市场，一个潜在的近期催化剂正在成形。\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">预计最早本季度将在日本获得结直肠癌适应症的监管批准。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">与美国碎片化的保险体系不同，日本实行单一国家医保制度，一旦获批，\u003C\u002Fspan>Signatera\u003Cspan style=\"font-family: DengXian;\">有望在全国范围内同步获得准入资格，市场开放效率远高于美国。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">Natera\u003Cspan style=\"font-family: DengXian;\">首席执行官\u003C\u002Fspan>Steve Chapman\u003Cspan style=\"font-family: DengXian;\">描绘了一个更宏大的愿景：每一位癌症幸存者在确诊时即完成基因测序，此后每隔数月接受一次血液监测。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">但这一市场不会长期由\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">独享。\u003C\u002Fspan>Guardant Health\u003Cspan style=\"font-family: DengXian;\">目前是最接近的竞争对手，\u003C\u002Fspan>Tempus AI\u003Cspan style=\"font-family: DengXian;\">和罗氏则构成更长期的竞争威胁。\u003C\u002Fspan>Natera\u003Cspan style=\"font-family: DengXian;\">去年收购\u003C\u002Fspan>Foresight Diagnostics\u003Cspan style=\"font-family: DengXian;\">，被视为巩固技术领先优势的战略举措。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FN\u002FNTRA\u002FNTRA.jpg","2026-05-15T14:46:22","2026.05.15","2026\u002F05\u002F15",58993,[22],"NTRA","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":68,"summaryHtml":73,"aboutTitle":74,"aboutHtml":75,"copyrightHtml":76},[44,47,50,53,56,59,62,65],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":60,"url":61},"美股课程","\u002Fcol\u002Fvideos",{"label":63,"url":64},"免责声明","\u002Fdisclaimer",{"label":66,"url":67},"联系我们","\u002FContactUs",[69,70,71,72],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":78,"search":79,"searchPlaceholder":79,"hotContent":80,"draft":81,"noData":82,"searchNoData":83,"edit":84,"editVideo":85,"courseContent":86,"more":87,"buyNow":88,"subscribeNow":89,"encoding":90,"paidContent":91},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]